CASCADIAN THERAPEUTICS, INC. (NASDAQ:CASC) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August 8, 2017, Cascadian Therapeutics, Inc. (the “Company”) issued a press release regarding the Company’s financial results for the quarter ended June 30, 2017 and providing a corporate update. A copy of the Company’s press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
The information in this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be incorporated by reference into any other filing with the U.S. Securities and Exchange Commission, whether made before, on or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
|Item 9.01||Financial Statements and Exhibits.|
|99.1||Press Release issued by Cascadian Therapeutics, Inc. dated August 8, 2017.|
Cascadian Therapeutics, Inc. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE ex99-1.htm Cascadian Therapeutics 8-K Exhibit 99.1 Cascadian Therapeutics Reports Second Quarter 2017 Financial Results First Patients Randomized in Western Europe and Australia in Ongoing Global HER2CLIMB Registrational Trial of Tucatinib Conference Call Scheduled for Today at 4:30 p.m. ET SEATTLE,…To view the full exhibit click
About CASCADIAN THERAPEUTICS, INC. (NASDAQ:CASC)
Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.